Lucid Diagnostics/LUCD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.

Ticker

LUCD

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Lishan Aklog

Employees

70

Headquarters

New york, United States

LUCD Metrics

BasicAdvanced
$46M
Market cap
-
P/E ratio
-$1.27
EPS
-
Beta
-
Dividend rate
$46M
$1.85
$0.63
219K
1.381
1.36
126.207
-115.88%
-248.82%
15.557
4.28
370.50%
20.86%

What the Analysts think about LUCD

Analyst Ratings

Majority rating from 6 analysts.
Buy

LUCD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,060.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
0.00%
Net income
-$11M
-1.85%
Profit margin
-1,060.00%
-1.85%

LUCD Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 49.25%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.27
-$0.34
-$0.25
-$0.40
-
Expected
-$0.32
-$0.27
-$0.26
-$0.27
-$0.23
Surprise
-15.89%
24.77%
-3.03%
49.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lucid Diagnostics stock?

Lucid Diagnostics (LUCD) has a market cap of $46M as of June 17, 2024.

What is the P/E ratio for Lucid Diagnostics stock?

The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of June 17, 2024.

Does Lucid Diagnostics stock pay dividends?

No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Lucid Diagnostics dividend payment date?

Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.

What is the beta indicator for Lucid Diagnostics?

Lucid Diagnostics (LUCD) does not currently have a Beta indicator.

What is the Lucid Diagnostics stock price target?

The target price for Lucid Diagnostics (LUCD) stock is $3.83, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Lucid Diagnostics stock

Buy or sell Lucid Diagnostics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing